Product Details

2-(4-Fluorophenyl)-5-[(5-iodo-2-methylphenyl)methyl]thiophene

详情介绍:

2-(4-Fluorophenyl)-5-[(5-iodo-2-methylphenyl)methyl]thiophene
CAS N0.:898566-17-1
Usage: Canagliflozin Intermediates
Molecular Formula:C18H14FIS
Content: 99%min
in stock
other intermediates:5-Iodo-2-methylbenzoic acid [CAS NO.: 54811-38-0]
2-(5-BroMo-2-Methylbenzyl)-5-(4-fluorophenyl)thiophene [CAS NO.:1030825-20-7]
Canagliflozin hemihydrate  [CAS NO.:928672-86-0]

Diabetes can be divided into insulin-dependent (type I) and non-insulin dependent (type II), including type II diabetes is most common, accounting for more than90%of diabetic patients.Because the pathogenesis of diabetes complicated mankind has yet to find a cure for, which means that patients need lifelong treatment. As the pathophysiology of diabetes-depth understanding of different pathophysiological aspects of drug development is increasing. sodium-glucose co-transporter is currently developing a new, efficient one of hypoglycemic agents. It inhibits the activity of SGLT-2to enhance incretion activity, thereby reducing blood sugar, diabetes; drug therapy has become the new focus.
For the present,sodium-glucose co-transporter 2(SGLT2) inhibitors have become a potentially new therapeutic approach for the treatment of type 2 diabetes,and they could lower the blood glucose levels by inhibiting glucose reabsorption in the renal proximal tubules.They conclude C-aryl inhibitor,O-aryl inhibitor,S-aryl inhibitor,and N-aryl inhibitor,but C-aryl inhibitor and O-aryl inhibitor are in the hot research.Several SGLT2 inhibitors in development(dapagliflozin,canagliflozin,ASP1941,BI10773,and LX4211) have demonstrated the improvement in glycemic control and weight loss,along with slight adverse effects.
Shanghai Yongzeng Chemical Company limited



Diabetes can be divided into insulin-dependent (type I) and non-insulin dependent (type II), including type II diabetes is most common, accounting for more than90%of diabetic patients.Because the pathogenesis of diabetes complicated mankind has yet to find a cure for, which means that patients need lifelong treatment. As the pathophysiology of diabetes-depth understanding of different pathophysiological aspects of drug development is increasing. sodium-glucose co-transporter is currently developing a new, efficient one of hypoglycemic agents. It inhibits the activity of SGLT-2to enhance incretion activity, thereby reducing blood sugar, diabetes; drug therapy has become the new focus.
For the present,sodium-glucose co-transporter 2(SGLT2) inhibitors have become a potentially new therapeutic approach for the treatment of type 2 diabetes,and they could lower the blood glucose levels by inhibiting glucose reabsorption in the renal proximal tubules.They conclude C-aryl inhibitor,O-aryl inhibitor,S-aryl inhibitor,and N-aryl inhibitor,but C-aryl inhibitor and O-aryl inhibitor are in the hot research.Several SGLT2 inhibitors in development(dapagliflozin,canagliflozin,ASP1941,BI10773,and LX4211) have demonstrated the improvement in glycemic control and weight loss,along with slight adverse effects.
Shanghai Yongzeng Chemical Company limited


 

Contact Us
Our Staff is at Your Service

Zeng Yan
Tel:  +86-21-6528 1118
Fax: +86-21-6528 2963
Cell Phone:  13818947575
Http://www.allyzchem.com
Add:   205, No.3, Lane 439, Guangyue Road,Shanghai,200434,China

Mr.Lee
Tel:  +86-21-6592 5639
Fax: +86-21-6528 2963
Cell Phone: 15921781258
Http://www.allyzchem.com
Add: 205, No.3, Lane 439, Guangyue Road,Shanghai,200434,China

沪公网安备 31010902002464号